



TOP 50

CELL & GENE THERAPY COMPANIES IN ASIA PACIFIC

INTRODUCTION

A region defining the future of advanced therapies

Asia Pacific is becoming an increasingly important centre for cell and gene therapy innovation, with companies across China, Japan, South Korea, Australia, India, Singapore and Taiwan advancing programmes across multiple therapeutic modalities.

The regional pipeline is expanding beyond traditional CAR-T approaches to include next-generation CAR-T, CAR-NK, gene editing, iPSC-derived therapies, allogeneic cell therapies and gene therapy.

At the same time, developers are facing the practical challenges of translating scientific innovation into clinical and commercial products — clinical development, CMC readiness, manufacturing scale-up, regulatory pathways, supply chain requirements and market access.

This eBook highlights **50 companies** with active or advancing cell and gene therapy pipelines across Asia Pacific.

CAR-T

CAR-NK

Gene editing

iPSC-derived

Allogeneic

Gene therapy

Regenerative medicine

1

**JW Therapeutics**

CAR-T, T-cell therapy

CHINA

2

**Legend Biotech**

CAR-T

CHINA

3

**Fosun Kite**

CAR-T

CHINA

4

**CARsgen Therapeutics**

CAR-T, next-generation CAR-T

CHINA

5

**IASO Biotherapeutics**

CAR-T

CHINA

6

**CBMG**

CAR-T, cell therapy

CHINA

7

**ImmuneOnco Biopharma**

Cell therapy, immunotherapy

CHINA

8

**PersonGen BioTherapeutics**

CAR-T, cell therapy

CHINA

9

**SinoCellTech**

Cell therapy

CHINA

10

**Gracell Biotechnologies / AstraZeneca**

CAR-T, next-generation cell therapy

CHINA

11

Cabaletta Bio®

Cabaletta BioCAR-T,
autoimmune cell
therapy

CHINA / US

12

NOILE-IMMUNE
BIOTECH**Noile-
Immune
Biotech**

CAR-T

JAPAN

13

Sumitomo Pharma

**Sumitomo
Pharma**iPSC-derived cell
therapy

JAPAN

14

JCR
Pharmaceuticals**JCR
Pharmaceuticals**Regenerative
medicine, cell
therapy

JAPAN

15

Healios

HealiosRegenerative
medicine

JAPAN

16

TaKaRa

Takara BioGene therapy, cell
therapy

JAPAN

17

AnGes

AnGes

Gene therapy

JAPAN

18

Heartseed

HeartseediPSC-derived
cardiac cell
therapy

JAPAN

19

NIPRO
Live Longer. Live Better.**Nipro**Regenerative
medicine

JAPAN

20

J-TEC

**Japan Tissue
Engineering**Regenerative
medicine, cell
therapy

JAPAN

21


CUROCELL
Curocell

CAR-T

SOUTH KOREA

22


GC Cell
GC Cell

CAR-NK, cell therapy

SOUTH KOREA

23


MEDIPOST
Medipost

Stem cell therapy

SOUTH KOREA

24


PHARMICELL
Pharmicell

Stem cell therapy

SOUTH KOREA

25


ANTEROGEN
Anterogen

Stem cell therapy

SOUTH KOREA

26


CHA Biotech
CHA Biotech

Cell therapy, regenerative medicine

SOUTH KOREA

27


HELI XMITH
Helixmith

Gene therapy

SOUTH KOREA

28


ToolGen
ToolGen

Gene editing, CAR-T

SOUTH KOREA

29


NKMAX
NKMax

NK-cell therapy

SOUTH KOREA

30


ENCell
ENCell

Cell therapy

SOUTH KOREA

31

**ImmunoACT**

CAR-T

INDIA

32

**Immuneel
Therapeutics**

CAR-T

INDIA

33

**Eyestem
Research**

Cell therapy

INDIA

34

**Stempeutics
Research**

Stem cell therapy

INDIA

35

**Mesoblast**Mesenchymal
stem cell therapy

AUSTRALIA

36

**Cynata
Therapeutics**iPSC-derived cell
therapy

AUSTRALIA

37

**Cartherics**CAR-NK, iPSC-
derived therapy

AUSTRALIA

38

**Carina
Biotech**

CAR-T

AUSTRALIA

39

**Chimeric
Therapeutics**

CAR-T

AUSTRALIA

40

**Tessa
Therapeutics**

T-cell therapy

SINGAPORE

41

**SCG Cell Therapy**

CAR-T, cell therapy

SINGAPORE

42

**Tikva AlloCell**

Allogeneic CAR-T

SINGAPORE

43

**Steminent Biotherapeutics**

Cell therapy

TAIWAN

44

**UWELL Biopharma**

CAR-T, CAR-NK

TAIWAN

45

**Medigen Biotechnology**

Advanced biologics / cell therapy

TAIWAN

46

**TaiMed Biologics**

Cell and gene therapy-related development

TAIWAN

47

**Astellas Pharma**

Gene therapy, regenerative medicine

JAPAN

48

**Kyowa Kirin**

Hematopoietic stem-cell gene therapy

JAPAN

49

**Daiichi Sankyo**

Cell therapy / gene therapy research

JAPAN

50

**Otsuka Pharmaceutical**

Regenerative medicine / gene therapy

JAPAN

THE NEXT PHASE

From Pipeline to Patient: the next phase of CGT in Asia Pacific

The companies featured here demonstrate the breadth of cell and gene therapy development across Asia Pacific — from CAR-T and gene editing to iPSC-derived therapies, CAR-NK and allogeneic approaches.

The next challenge is translating these promising pipelines into therapies that can be manufactured at scale, approved efficiently and made accessible to patients — requiring closer collaboration across discovery, clinical development, CMC, manufacturing, regulatory, supply chain and market access.

Innovation & Translation

Next-Gen Cell & Gene Therapies

Vector Engineering & Delivery

Manufacturing Scale-Up & CMC

Technology Transfer

CGT Supply Chain

Smart Manufacturing

Regulatory Pathways

Market Access



Cell & Gene Therapy World Asia 2027

23–24 March 2027 · Sands Expo & Convention Centre, Singapore

From Innovation to Translation. From Manufacturing to Market.